Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]

Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gane E, et al. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-STAR part B [abstract 195]. Presented at the Liver Meeting 2017, October 22. Washington, DC; 2017.

Publication Type:

Conference Proceedings

Source:

Presented at the Liver Meeting 2017, October 22, Washington, DC (2017)
Top